Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)

14. juli 2016 opdateret af: Washington University School of Medicine
The purpose of this research study is to study the safety and immune response of people who receive a personalized dendritic cell vaccine with the intention of stimulating the immune system to react to lung cancer cells.

Studieoversigt

Status

Trukket tilbage

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Tumor vaccines represent a promising area of clinical investigation in solid tumors based on evidence of clinical activity and minimal toxicity. The underlying hypothesis of this research is that immunization against tumor neoantigens is effectively required to elicit antigen-reactive T cells capable of recognizing and eliminating cancer. Moreover, both quantitative and qualitative improvements in CD8 immunity are necessary (but not sufficient) for clinical response and improved survival. The goal of this study is to build on our prior clinical trial results in melanoma by studying the immune response to tumor neoantigens in patients with stage 1 NSCLC.

Undersøgelsestype

Interventionel

Fase

  • Tidlig fase 1

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with completely resected stage I non-small cell lung cancer who are not considered for adjuvant post operative therapy.
  • Age ≥ 18 years.
  • ECOG performance status 0-1.
  • HLA-A2 positive.

  • Required initial laboratory values (submitted within 14 days prior to registration):

    • WBC > 3,000/mm3
    • Hg ≥ 9.0 gm/dL
    • Platelets >75,000/mm3
    • Serum bilirubin < 2.0 mg/dL
    • Serum creatinine < 2.0 mg/dL
  • Sexually active women of childbearing potential must use effective birth control during the trial and for at least two months following the trial, and sexually active men must be willing to avoid fathering a new child while receiving therapy.
  • Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion Criteria:

  • Prior treatment with cytotoxic chemotherapy
  • Prior treatment with targeted therapy or immunotherapy.
  • Active untreated CNS metastasis.
  • Active infection.
  • Prior malignancy (except non-melanoma skin cancer) within 3 years.
  • Pregnant or nursing.
  • Concurrent treatment with systemic corticosteroids; local (inhaled or topical) steroids are permitted.
  • Known allergy to eggs.
  • Prior history or uveitis or autoimmune inflammatory eye disease.
  • Known positivity for hepatitis B sAg, hepatitis C antibody, or HIV antibody.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Surgery/Apheresis/Cyclophosphamide/Vaccine
  • Standard of care surgery
  • Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery
  • Cyclophosphamide 300 mg/m^2 intravenously (Day -4)
  • Personalized vaccine (Day 1)
  • Booster dose of personalized vaccine (Day 43)
  • Booster dose of personalized vaccine (Day 85)
Medicin: Cyclofosfamid
Andre navne:
  • Cytoxan®
Procedure: Aferese
Procedure: Standard of care surgery
Biologisk: Personalized mature dendritic cell vaccine

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Immunological response as measured by increased numbers of peptide specific CD8+ T cells as calculated by the tetramer assay
Tidsramme: 1 year
-Blood for immunological response is drawn every week from Dose #1 to 6 weeks after Dose #3 (Day 1 to Day 126 = Week 18 and then every 4 weeks until Day 365)
1 year
Safety and tolerability of vaccine as measured by adverse events experienced and graded by NCI CTCAE Version 4.0
Tidsramme: 30 days after last vaccine (approximately Day 115)

Safety will be closely monitored after vaccination. Patients will be observed for 2 hours after the first dose and vital signs recorded every 30 minutes during that time period beginning at the start of the infusion. For each dose thereafter, patients will be observed in the treatment area for 30 minutes after the infusion. The following parameters will be assessed:

  • Local signs and symptoms
  • Systemic signs and symptoms
  • Laboratory evaluations
  • Adverse and serious adverse events
  • Toxicity will be graded according to the NCI's CTCAE version 4.0.
30 days after last vaccine (approximately Day 115)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Time to progression (TTP)
Tidsramme: 5 years
These patients have been completed resected so there is no tumor response to monitor. CT scans evaluating for progression will be performed at baseline, following the third vaccine dose, and as per routine care during follow-up (generally every 3 months for the first year and every 6 months for the next 4 years thereafter).
5 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Washington University School of Medicine

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juli 2016

Primær færdiggørelse (Forventet)

1. oktober 2019

Studieafslutning (Forventet)

1. oktober 2023

Datoer for studieregistrering

Først indsendt

4. februar 2015

Først indsendt, der opfyldte QC-kriterier

16. april 2015

Først opslået (Skøn)

17. april 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

18. juli 2016

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. juli 2016

Sidst verificeret

1. juli 2016

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 15-x043

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Ikke-småcellet lungekræft

Kliniske forsøg med Cyclofosfamid

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Albania

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner